News Release

Medidata Opens New, Larger London EMEA Headquarters

Europe/EMEA Experiencing Rapid Growth, Expanded New Facilities to Meet Demand

NEW YORK--(BUSINESS WIRE)--Sep. 27, 2017-- Medidata (NASDAQ:MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced the official opening of its new EMEA headquarters at 12 Hammersmith Grove, London, to facilitate the company’s continued expansion in the region.

Europe is one of Medidata’s fastest growing markets, serving various customers, including big pharma, biotech and medtech companies and leading CROs. The Company has a strong and increasing presence in the region, with offices in London and Dusseldorf and a data center in Frankfurt, with plans to expand into additional European Life Sciences hubs.

London has been the location of the Company’s EMEA Headquarters for over ten years and serves as a pivotal hub for the region’s sales and marketing operations and a global hub for R&D. Medidata has built a strong workforce in London of over 240 highly skilled employees and has established long term, trusted relationships with customers in the UK, including AstraZeneca, GlaxoSmithKline, Novartis and Roche.

“I am delighted that Medidata are reaffirming their commitment to Hammersmith and London as they move into their brand new and improved EMEA headquarters. The UK life sciences sector is globally leading, with a scientific, regulatory and industrial centre of excellence,” said Philip Dunne MP, Minister of State for Health. “As a government, we are deeply committed to helping the life sciences sector flourish and it gives me great pleasure to celebrate this achievement with Medidata, as the company continues its work improving patient lives.”

“We chose London as our EMEA headquarters over ten years ago due to the high concentration of innovative, international life sciences companies, a strong R&D presence and a talented, diverse workforce. The UK continues to be an attractive market for Medidata,” said Tarek Sherif, Medidata Chairman and CEO. “This is an important investment for the Company, demonstrating our increased commitment to the UK and the strategic importance of the EMEA region. We are delighted to move to new, expanded headquarters in London that will provide space to attract new talent over the next few years. I look forward to leveraging the opportunities provided by this expansion to meet the strong growth demand in the region and continue to attract and retain talented and skilled employees.”

The Company hosted an opening reception at 12 Hammersmith Grove on the 26th of September. Medidata executive management, including Tarek Sherif (Chairman and CEO), Glen de Vries (President), Mike Capone (Chief Operating Officer) and Christian Hebenstreit (Managing Director, EMEA) were present to celebrate this landmark with Medidata employees, customers and members of the local council.

About Medidata

Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.

Source: Medidata Solutions

Medidata Solutions:
Anthony D’Amico, +1-732-767-4331
Erik Snider, +1-646-362-2997

Investor Contact

Betsy Frank
+1 917 522 4620